Clinical and Economic Outcomes Associated with Low-Dose Fluticasone Propionate Versus Montelukast in Children with Asthma Aged 4 to 11 Years

Table 2.: Unadjusted Outcomes in the Follow-Up Period by Matched Cohorts

Outcomes	FP44 (N=2,212)	MON (N=4,424)	p-Value
Asthma-Related Events
ED visit rate^*	3.40	4.76	0.037
Hospitalization/ED visit rate^*	4.07	5.29	0.075
Monthly Asthma-Related Costs
Medical costs, mean (SD)	$26 ($165)	$27 ($176)	0.852
Pharmacy costs, mean (SD)	$21 ($87)	$48 ($75)	<0.001
Total costs, mean (SD)	$48 ($190)	$75 ($197)	<0.001
Monthly Rescue Medication Use
Number of SABA canisters, mean (SD)	0.11 (0.24)	0.11 (0.26)	0.963
Number of OCS prescriptions, mean (SD)	0.03 (0.10)	0.04 (0.04)	<0.001

^* Rate is per 100 person-years. FP 44= Fluticasone propionate 44mcg, MON= montelukast, ED = emergency department, SD = standard deviation, SABA = short acting betaagonists, OCS = oral corticosteroids.